来源不明的栓塞性中风:诊断不确定性的心血管方法。

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Adishwar Rao, Hammad Rahman, Hitesh Bhatia, Akriti Agrawal, Asna Aafreen, Saurabh Sharma, Carlos Y Lopez, Edo Kaluski
{"title":"来源不明的栓塞性中风:诊断不确定性的心血管方法。","authors":"Adishwar Rao, Hammad Rahman, Hitesh Bhatia, Akriti Agrawal, Asna Aafreen, Saurabh Sharma, Carlos Y Lopez, Edo Kaluski","doi":"10.1016/j.carrev.2025.08.008","DOIUrl":null,"url":null,"abstract":"<p><p>Embolic stroke of undetermined source (ESUS) is a clinical event with an undelineated embolic etiology after the initial stroke workup. Once stroke specialists confirm ESUS, evaluation of rhythm disorders such as atrial fibrillation, specific cardiac pathologies (cardiomyopathy, left atrial cardiopathy, left-atrial septal pouch, aortic or mitral valve disease, cardiac neoplasm, right-to-left shunts, or device-related thrombus), and acquired hypercoagulable states, which may occasionally be related to malignancy, should be performed. While most ESUS patients require appropriate antiplatelet therapy, certain subsets may require oral anticoagulation. However, routine prescription of oral anticoagulants in the absence of documented atrial fibrillation, cancer-related thrombosis, or cardiac thrombosis is discouraged. Shared decision-making between the patient and the physician about additional diagnostic and therapeutic decisions is particularly encouraged in this condition, given the limited availability of high-quality clinical data and considerable uncertainty about the safety and efficacy of therapeutic options and clinical outcomes.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Embolic stroke of undetermined source: A cardiovascular approach to diagnostic uncertainty.\",\"authors\":\"Adishwar Rao, Hammad Rahman, Hitesh Bhatia, Akriti Agrawal, Asna Aafreen, Saurabh Sharma, Carlos Y Lopez, Edo Kaluski\",\"doi\":\"10.1016/j.carrev.2025.08.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Embolic stroke of undetermined source (ESUS) is a clinical event with an undelineated embolic etiology after the initial stroke workup. Once stroke specialists confirm ESUS, evaluation of rhythm disorders such as atrial fibrillation, specific cardiac pathologies (cardiomyopathy, left atrial cardiopathy, left-atrial septal pouch, aortic or mitral valve disease, cardiac neoplasm, right-to-left shunts, or device-related thrombus), and acquired hypercoagulable states, which may occasionally be related to malignancy, should be performed. While most ESUS patients require appropriate antiplatelet therapy, certain subsets may require oral anticoagulation. However, routine prescription of oral anticoagulants in the absence of documented atrial fibrillation, cancer-related thrombosis, or cardiac thrombosis is discouraged. Shared decision-making between the patient and the physician about additional diagnostic and therapeutic decisions is particularly encouraged in this condition, given the limited availability of high-quality clinical data and considerable uncertainty about the safety and efficacy of therapeutic options and clinical outcomes.</p>\",\"PeriodicalId\":47657,\"journal\":{\"name\":\"Cardiovascular Revascularization Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Revascularization Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.carrev.2025.08.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2025.08.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

来源不明的栓塞性卒中(ESUS)是一种临床事件,在最初的卒中检查后,栓塞性病因不明。一旦卒中专家确认ESUS,应评估心律失常,如房颤、特定心脏病变(心肌病、左心房心脏病、左房间隔囊、主动脉或二尖瓣疾病、心脏肿瘤、右至左分流或器械相关血栓)和获得性高凝状态,这可能偶尔与恶性肿瘤有关。虽然大多数ESUS患者需要适当的抗血小板治疗,但某些亚群可能需要口服抗凝。然而,在没有房颤、癌症相关血栓形成或心脏血栓形成的情况下,不鼓励常规口服抗凝剂处方。考虑到高质量临床数据的可用性有限,以及治疗方案和临床结果的安全性和有效性存在相当大的不确定性,在这种情况下,特别鼓励患者和医生就额外的诊断和治疗决策进行共同决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Embolic stroke of undetermined source: A cardiovascular approach to diagnostic uncertainty.

Embolic stroke of undetermined source (ESUS) is a clinical event with an undelineated embolic etiology after the initial stroke workup. Once stroke specialists confirm ESUS, evaluation of rhythm disorders such as atrial fibrillation, specific cardiac pathologies (cardiomyopathy, left atrial cardiopathy, left-atrial septal pouch, aortic or mitral valve disease, cardiac neoplasm, right-to-left shunts, or device-related thrombus), and acquired hypercoagulable states, which may occasionally be related to malignancy, should be performed. While most ESUS patients require appropriate antiplatelet therapy, certain subsets may require oral anticoagulation. However, routine prescription of oral anticoagulants in the absence of documented atrial fibrillation, cancer-related thrombosis, or cardiac thrombosis is discouraged. Shared decision-making between the patient and the physician about additional diagnostic and therapeutic decisions is particularly encouraged in this condition, given the limited availability of high-quality clinical data and considerable uncertainty about the safety and efficacy of therapeutic options and clinical outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiovascular Revascularization Medicine
Cardiovascular Revascularization Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.30
自引率
5.90%
发文量
687
审稿时长
36 days
期刊介绍: Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信